# A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

> **NCT05604261** · PHASE2 · UNKNOWN · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Reflux Esophagitis
- Gastroesophageal Reflux
- Esophagitis
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Gastrointestinal Diseases

## Interventions

- **DRUG:** Anaprazole sodium 40 mg
- **DRUG:** Anaprazole sodium 60 mg
- **DRUG:** Rabeprazole sodium 20 mg

## Key facts

- **NCT ID:** NCT05604261
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2023-07
- **Final completion:** 2024-03
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2022-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05604261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05604261, "A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05604261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*